Mangoceuticals (MGRX) stock price is $0.20, up 5.26% on the day, as of Nov 9, 2026. It has a market cap of $3.37Mn, and is classified in the Telehealth industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap3.37 Mn
P/E-0.21
FCF (Yr)-5.85 Mn
ROA (Yr)-131.24
EV to EBIT-0.08
Net Income (Yr)-20.64 Mn
Enterprise Value1.00 Mn
Add ratio to table…
About
Mangoceuticals, Inc. is a telehealth and wellness company that connects consumers with licensed healthcare professionals through its website and provides access to a range of men’s health products.
The company generates revenue primarily from the sale of its compounded pharmaceutical products, which include treatments for erectile dysfunction, hair loss, hormone balance and weight management, as well as the FDA approved testosterone therapy product marketed under the…
Mangoceuticals, Inc. is a telehealth and wellness company that connects consumers with licensed healthcare professionals through its website and provides access to a range of men’s health products.
The company generates revenue primarily from the sale of its compounded pharmaceutical products, which include treatments for erectile dysfunction, hair loss, hormone balance and weight management, as well as the FDA approved testosterone therapy product marketed under the Prime brand. Customers can also purchase these products on a subscription basis to receive regular refills, providing the company with recurring revenue.
Mangoceuticals operates in a competitive market that includes telehealth providers such as Hims & Hers and Roman as well as large pharmaceutical companies like Pfizer, Eli Lilly and Merck that sell branded erectile dysfunction, hair loss and hormone therapies. Its competitive advantages stem from the sublingual delivery format of its products, the integration of telehealth consultations with pharmacy fulfillment, and its focus on branding and direct to consumer marketing.
The company serves adult men who seek treatment for conditions such as erectile dysfunction, hair loss, hormone imbalance and weight management through its telehealth platform. It also serves patients who obtain prescriptions for the FDA approved testosterone therapy product via the same telehealth service.
Sector:HealthcareSector rationaleThe company's primary revenue is generated from the sale of compounded pharmaceutical products and FDA-approved testosterone therapy, which falls under Pharmaceuticals and Drug Distribution in Healthcare. A secondary sector of Technology is justified because the company operates a telehealth platform that connects consumers with licensed professionals, representing a distinct digital service delivery model.Industries:TelehealthTelehealthPrimaryMangoceuticals operates a telehealth platform that connects consumers with licensed healthcare professionals for consultations. Its revenue model includes consultation fees and the associated pharmacy fulfillment of prescriptions for men's health conditions.Generic DrugsGeneric DrugsSecondaryThe company generates primary revenue from the sale of compounded pharmaceutical products for erectile dysfunction, hair loss, and hormone balance, which fall under specialty pharmaceuticals.Classified using BQ-MICSCIK: 0001938046
Peer percentiles
How Mangoceuticals ranks
Ranked against the 102 companies in Healthcare Providers·58 metrics · as of Nov 6, 2026
Valuation
12 metrics · Lower multiples rank higher; a negative multiple ranks last